A Study of RO5186582 Treatment on Cytochrome P450 (CYP) 3A4 Activity in Healthy Participants
Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
This is a non-randomized, open-label, five treatment, fixed sequence cross-over study to
investigate the effect of RO5186582 treatment on CYP3A activity using midazolam as a probe
CYP3A substrate, and also to assess the pharmacodynamic measures of brain electrical activity
and sedation to explore the pharmacodynamic interaction between the gama-amino butyric acid
(GABA)A negative allosteric modulator RO5186582 and the prototypical GABAA positive
allosteric modulator midazolam. The anticipated study duration is up to nine weeks.